A novel gene recombinant collagen hemostatic sponge with excellent biocompatibility and hemostatic effect

Effect and biosafety are the most noteworthy aspect of the hemostatic materials for trauma treatment. In this work, we evaluated the biocompatibility and hemostatic effect of a novel recombinant collagen hemostatic sponge according to ISO 10993. In addition, the interaction between the recombinant collagen hemostatic sponge and blood cells was observed by scanning electron microscopy, moreover, the hemostatic effect was evaluated by blood clotting assay in vitro and liver hemorrhage models in vivo. As the results, the novel recombinant collagen hemostatic sponge enables to be biodegradable completely in vivo, without stimulation, sensitization, acute toxicity, hematolysis or obvious immune rejection. The procoagulant effect of recombinant hemostatic sponge in vitro is significantly more excellent than that of natural collagen sponge due to the more promotive capacity of blood cell adhesion. Meanwhile, the liver hemorrhage models showed that the hemostatic time of recombinant collagen sponge was 19.33 ± 4.64 s, which was significantly better than that of natural collagen sponge (hemostatic time 31.62 ± 5.63 s). Therefore, the novel recombinant collagen hemostatic sponge with satisfactory biocompatibility and significant hemostatic effect can be performed as a potential novel type of clinical hemostatic products for research and development.